Ainos 5/12/2023 Earnings Report

Ainos EPS Results

• Actual EPS: -$0.13
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Ainos Revenue Results

• Actual Revenue: $0.05 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Ainos Announcement Details

• Date: 5/12/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Ainos (OTCMKTS:AIMD) (OTCMKTS: AIMD) is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapeutics for cardiovascular and metabolic diseases. The company’s lead candidates include novel oral agents designed to modulate key biochemical pathways implicated in heart failure and diabetic complications. Leveraging proprietary small-molecule platforms, Ainos aims to offer differentiated treatment options that address unmet medical needs and improve patient outcomes.

Since its founding in 2012, Ainos has advanced multiple product candidates through preclinical research and early-stage clinical trials. The company has built a pipeline that combines selective receptor modulators and enzyme inhibitors, and it maintains collaborations with academic institutions for biomarker discovery and translational research. Ainos has also invested in scalable manufacturing processes to support potential commercial launch and to ensure supply chain reliability for its specialized oral dosage forms.

Ainos maintains a global presence, with research and development operations in the United States and Europe. Its U.S. headquarters are located in Cambridge, Massachusetts, while a dedicated clinical development office operates in Berlin, Germany. The company also engages with strategic partners in Asia to facilitate regional trial enrollment and to explore opportunities for local licensing agreements. By aligning regulatory and market access efforts across multiple geographies, Ainos seeks to shorten development timelines and maximize patient reach.

The company is led by a management team with deep experience in pharmaceutical development and regulatory affairs. Chief Executive Officer Dr. Margaret Liu, a veteran of several cardiovascular drug approvals, oversees strategic planning and corporate partnerships. Chief Scientific Officer Dr. Aaron Patel directs preclinical research programs, drawing on more than two decades of expertise in small-molecule chemistry. Ainos’s board of directors comprises industry leaders and seasoned investors committed to advancing the company’s mission of delivering innovative therapies to patients worldwide.